Researcher index

Authors in the psilocybin and psilocin literature

Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.

Sharp Trevor

16 indexed publications match this author name.

ORCID: Not found in stored metadata
OpenAlex: Not found in stored metadata

Author watchlist

Create a confirmed email alert for new publications matching this author.

Topics

Receptor Pharmacology 10 Depression 7 Mechanism of Action 6 Neuroplasticity 4 Animal Study 4 Brain Imaging 4 OCD 3 Adverse Events 3 General 3 Anxiety 2 Pharmacology 2 Clinical Trial 2

Journals

British journal of pharmacology 2 Cureus 2 ACS chemical neuroscience 1 Comprehensive psychiatry 1 Exploration of neuroscience 1 Trends in molecular medicine 1 Frontiers in psychiatry 1 CNS spectrums 1

Publication history

Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.ACS chemical neuroscience · 2026-08-05 Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.British journal of pharmacology · 2026-07-01 Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.British journal of pharmacology · 2026-07-01 Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.Comprehensive psychiatry · 2025-10-01 The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?Exploration of neuroscience · 2025-08-07 Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.Cureus · 2025-01-01 Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.Cureus · 2025-01-01 Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin.Trends in molecular medicine · 2024-04-01 The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.Frontiers in psychiatry · 2024-01-01 Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.CNS spectrums · 2023-08-01 Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory miceTranslational Psychiatry · 2022-02-23 Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brainNeuropharmacology · 2015-12-01 ChemInform Abstract: CRYSTAL STRUCTURES OF THE TEONANACATL HALLUCINOGENS PART1, PSILOCYBIN C12H17N2O4OChemInform · 1974-09-03 ChemInform Abstract: CRYSTAL STRUCTURES OF THE TEONANACATL HALLUCINOGENS PART2, PSILOCIN C12H15N2OChemischer Informationsdienst · 1974-09-03 Crystal structures of the Teonanácatl hallucinogens. Part I. Psilocybin C12 H17 N2 O4 PJournal of the Chemical Society Perkin Transactions 2 · 1974-01-01 Crystal structures of the Teonanácatl hallucinogens. Part II. Psilocin, C12 H15 N2 OJ. Chem. Soc., Perkin Trans. 2 · 1974-01-01

Author directory